Purchase Order INR13PX80259

The Food and Drug Administration awarded a $20,745.32 firm fixed-price purchase order to Genscript USA Inc. on July 21, 2020, for monoclonal antibody production services. The contract, designated as a partial small business set-aside, is scheduled for completion by July 31, 2021, with work performed at Genscript's facility in Piscataway, New Jersey. Genscript USA Inc. is a biotechnology company specializing in advanced molecular biology services, including gene synthesis, protein production, and...

This is a $5,820 firm-fixed price purchase order awarded by the National Institutes of Health (NIH) to A&G Pharmaceutical, Inc. (doing business as Precision Antibody) for monoclonal antibody production services. The contract is not set-aside and was awarded under the NIH's Acquisition Operations. Precision Antibody is a for-profit manufacturer of specialized biological materials and services, including custom antibody development, cell lines, and peptide synthesis, in support of biomedical...

This is a Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey. The contract is for the provision of monoclonal antibody (mAb) development services, with a completion date of September 19, 2025, and a ceiling value of $13,062.24. The contract does not have a set-aside designation. Genscript USA Inc. is a for-profit organization that specializes in advanced...

This firm fixed price purchase order was awarded by the National Institutes of Health National Cancer Institute to Genscript USA Inc. for $30,280. The contract is for the acquisition of recombinant antibody against mouse ErbB2 (HER2) domain IV via custom protein production services. Specifically, Genscript will immunize rabbits with the antigen protein, collect B cell clones to screen for binding to mouse HER2, collect supernatants from 20 antibody clones, and produce and purify the...

The U.S. Food and Drug Administration (FDA) awarded an $272.4K firm fixed-price purchase order to Antibody Solutions for the production of monoclonal antibodies production clones. The contract, designated as a Total Small Business set-aside, was awarded on August 1, 2024, with an ultimate completion date of July 31, 2029. Performance will take place at the contractor's facility in Santa Clara, California. This procurement supports the FDA's regulatory and scientific mission, as monoclonal...

This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $3,800.00, is for custom monoclonal antibody production services to support NIAID's biomedical research and public health initiatives. This contract does not have a set-aside designation. Genscript...

The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $132,862.50 firm fixed price delivery order contract to A&G Pharmaceutical, Inc., doing business as Precision Antibody, to support the agency's research efforts. Under the contract, TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ, Precision Antibody will provide monoclonal cell...

The National Institute of Standards and Technology awarded a purchase order to Sigma-Aldrich, Inc. for manufacturing monoclonal antibody expressed from the NISTCHO cell on February 5, 2025, with a ceiling value of $500,000.00 and firm fixed-price terms. Performance is located in Great Britain, United Kingdom. The requirement involves development and scale-up of upstream and downstream processes to produce 1–5 kilograms of monoclonal antibody reference material from a single bioreactor run,...

The U.S. government awarded a purchase order valued at $5,075.85 to Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey, for monoclonal antibody products. The contract, awarded on September 19, 2016, with an ultimate completion date of March 20, 2017, was issued under a firm fixed-price pricing structure by a civilian federal agency (Southeast Area). No set-aside designation was applied to this award. The place of performance is located in Piscataway, New...

The U.S. government awarded a $6,576.20 firm fixed-price purchase order to Genscript USA Inc. for the production of rabbit polyclonal antibodies against the chicken PCD1-1 immunoglobulin V domain. The contract, awarded on June 12, 2023, with an ultimate completion date of December 29, 2023, was funded by a civilian Southeast Area agency. Work is to be performed in East Lansing, Michigan. This contract represents a non-set-aside award to the Piscataway, New Jersey-based biotechnology firm,...